DHNP-2023

DHNP-2023 is a small molecule drug candidate being developed by the South Korean pharmaceutical company Daehan Nupharm. It is currently in the formulation research stage for the treatment of both epilepsy and obesity. The drug is classified in the company's pipeline as an incrementally modified drug (IMD), suggesting it may be a new dosage form, salt, or delivery method of an existing active ingredient intended to improve therapeutic outcomes, safety, or patient compliance. While the specific chemical identity and molecular targets have not been publicly disclosed by the developer, the dual indication of epilepsy and obesity is characteristic of certain neuromodulatory agents or carbonic anhydrase inhibitors.